Ozanimod
Zeposia (ozanimod) is a small molecule pharmaceutical. Ozanimod was first approved as Zeposia on 2020-05-20. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis. The pharmaceutical is active against sphingosine 1-phosphate receptor 1 and sphingosine 1-phosphate receptor 5. In addition, it is known to target sphingosine 1-phosphate receptor 3, sphingosine 1-phosphate receptor 4, and sphingosine 1-phosphate receptor 2. Zeposia’s patent is valid until 2029-05-14 (FDA).
Trade Name |
Zeposia |
---|---|
Common Name |
ozanimod |
ChEMBL ID |
CHEMBL3707247 |
Indication |
relapsing-remitting multiple sclerosis |
Drug Class |
Immunomodulators |
Image (chem structure or protein)
$4,995
Want to know more?
Schedule a demo or contact us for additional purchasing options.
Every Drug Dataset Includes...
Full dataset compatible with-






Continually updated information available as a yearly subscription for individual drug-of-interest.